Literature DB >> 8673059

Risk factors for hepatic veno-occlusive disease following HLA-identical sibling bone marrow transplants for leukemia.

C Rozman1, E Carreras, C Qian, R P Gale, M M Bortin, P A Rowlings, R C Ash, R E Champlin, P J Henslee-Downey, R H Herzig, W Hinterberger, J P Klein, H G Prentice, J Reiffers, F E Zwaan, M M Horowitz.   

Abstract

The objective was to analyze risk factors for veno-occlusive disease of the liver (VOD) after allogeneic bone marrow transplantation. A cohort of 1717 recipients of HLA-identical sibling transplants for leukemia between 1988 and 1990, in 200 transplant teams worldwide, was studied. Patients were scored as having VOD if liver tissue showed typical histologic features or if they had all three of the following: (1) jaundice; (2) hepatomegaly and right upper quadrant abdominal pain; and (3) ascites and/or unexplained weight gain. Patients surviving more than 7 days post-transplant without histologic or any of these clinical features of VOD were classified as not having VOD. Patient-, disease- and transplant-related characteristics of 95 patients with VOD were compared to those of 1514 without VOD. Variables correlated with an increased risk of VOD were: pretransplant conditioning with busulfan and cyclophosphamide compared to total body radiation (relative risk (RR) 2.8; P < 0.0001), pretransplant fungal infection (RR 4.1; P = 0.011), pretransplant Karnofsky performance score < 90% (RR 1.9; P = 0.012), prior liver disease (RR 1.9; P = 0.05) and age > 20 years (RR 1.8; P = 0.05). In patients receiving radiation for conditioning, intravenous immune globulin decreased VOD risk (RR 0.26; P = 0.003). This analysis identifies risk factors for VOD. The data suggest several strategies for modifying transplant regimens to reduce VOD risk and which patients might be suitable subjects for trials of strategies of VOD prevention.

Entities:  

Mesh:

Year:  1996        PMID: 8673059

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  9 in total

1.  Antineoplastic agent busulfan regulates a network of genes related to coagulation and fibrinolysis.

Authors:  Janka Reimer; Sandra Bien; Sabine Ameling; Elke Hammer; Uwe Völker; Georg Hempel; Joachim Boos; Heyo K Kroemer; Christoph A Ritter
Journal:  Eur J Clin Pharmacol       Date:  2012-06       Impact factor: 2.953

Review 2.  Hematopoietic stem cell transplantation for acute myeloid leukemia: to whom, when, and how.

Authors:  John Magenau; Daniel R Couriel
Journal:  Curr Oncol Rep       Date:  2013-10       Impact factor: 5.075

3.  Overexpression of glutathione S-transferase A1-1 in ECV 304 cells protects against busulfan mediated G2-arrest and induces tissue factor expression.

Authors:  Christoph A Ritter; Bernhard Sperker; Markus Grube; Dana Dressel; Christiane Kunert-Keil; Heyo K Kroemer
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

4.  Impact of hepatitis C virus seropositivity on survival after allogeneic hematopoietic stem cell transplantation for hematologic malignancies.

Authors:  Carlos A Ramos; Rima M Saliba; Leandro de Pádua; Ola Khorshid; Elizabeth J Shpall; Sergio Giralt; Poliana A Patah; Chitra M Hosing; Uday R Popat; Gabriela Rondon; Issa F Khouri; Yago L Nieto; Richard E Champlin; Marcos de Lima
Journal:  Haematologica       Date:  2009-01-14       Impact factor: 9.941

5.  Prophylactic low-dose heparin or prostaglandin E1 may prevent severe veno-occlusive disease of the liver after allogeneic hematopoietic stem cell transplantation in Korean children.

Authors:  Joon Sup Song; Jong Jin Seo; Hyung Nam Moon; Thad Ghim; Ho Joon Im
Journal:  J Korean Med Sci       Date:  2006-10       Impact factor: 2.153

Review 6.  Hepatic venous outflow obstruction: three similar syndromes.

Authors:  Ulas-Darda Bayraktar; Soley Seren; Yusuf Bayraktar
Journal:  World J Gastroenterol       Date:  2007-04-07       Impact factor: 5.742

7.  Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation.

Authors:  Corey Cutler; Kristen Stevenson; Haesook T Kim; Paul Richardson; Vincent T Ho; Erica Linden; Carolyn Revta; Ruth Ebert; Diane Warren; Sung Choi; John Koreth; Philippe Armand; Edwin Alyea; Shelly Carter; Mary Horowitz; Joseph H Antin; Robert Soiffer
Journal:  Blood       Date:  2008-09-05       Impact factor: 22.113

8.  Low molecular weight heparin for the prevention of hepatic veno-occlusive disease (VOD) after hematopoietic stem cell transplantation: a prospective phase II study.

Authors:  D L Forrest; K Thompson; V G Dorcas; S H Couban; R Pierce
Journal:  Bone Marrow Transplant       Date:  2003-06       Impact factor: 5.483

9.  Safety and efficacy of high-dose ranimustine (MCNU) containing regimen followed by autologous stem cell transplantation for diffuse large B-cell lymphoma.

Authors:  Yoshihiro Kameoka; Tomoaki Akagi; Kazunori Murai; Hideyoshi Noji; Yuichi Kato; Osamu Sasaki; Shigeki Ito; Kenichi Ishizawa; Yoji Ishida; Ryo Ichinohasama; Hideo Harigae; Naoto Takahashi
Journal:  Int J Hematol       Date:  2018-07-24       Impact factor: 2.319

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.